Urinary Glycosaminoglycans: Characterization and Quantification.
Methods Mol Biol
; 2619: 61-69, 2023.
Article
in English
| MEDLINE | ID: covidwho-2229918
ABSTRACT
The growing body of evidence supports the potential of using urinary glycosaminoglycans (uGAGs) levels as biomarkers to guide diagnosis and as predictive biomarkers of treatment efficacy. Recently, studies have shown that, in addition to MPS, the prognosis and treatment of cancers and viral infections, including COVID-19, are enabled by characterization and/or traits by GAGs. Reliable and accessible detection and assay protocols of urinary GAGs are therefore of great support for laboratory workers and clinicians. Here we describe a semiquantitative and quantitative urinary glycosaminoglycans determination using 1,9-dimethylmethylene blue (DMB) and the characterization of uGAGs using thin layer chromatography (TLC).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mucopolysaccharidoses
/
COVID-19
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Methods Mol Biol
Journal subject:
Molecular Biology
Year:
2023
Document Type:
Article
Affiliation country:
978-1-0716-2946-8_5
Similar
MEDLINE
...
LILACS
LIS